Edition:
United States

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

1.23USD
3:59pm EST
Change (% chg)

$0.09 (+7.89%)
Prev Close
$1.14
Open
$1.15
Day's High
$1.26
Day's Low
$1.14
Volume
226,712
Avg. Vol
156,817
52-wk High
$4.48
52-wk Low
$1.01

Chart for

About

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral... (more)

Overall

Beta: 2.97
Market Cap(Mil.): $61.13
Shares Outstanding(Mil.): 53.63
Dividend: --
Yield (%): --

Financials

  TTPH.OQ Industry Sector
P/E (TTM): -- 32.78 36.27
EPS (TTM): -1.43 -- --
ROI: -60.16 13.04 12.64
ROE: -60.21 14.06 13.67

FDA approves Tetraphase Pharma's antibiotic

Tetraphase Pharmaceuticals Inc said on Monday U.S. health regulators approved its drug to treat complicated intra-abdominal infections, providing a new option to combat the growing threat from treatment-resistant bacteria.

Aug 27 2018

UPDATE 1-U.S. FDA approves Tetraphase Pharma's antibiotic

Aug 27 Tetraphase Pharmaceuticals Inc said on Monday U.S. health regulators approved its drug to treat complicated intra-abdominal infections, providing a new option to combat the growing threat from treatment-resistant bacteria.

Aug 27 2018

U.S. FDA approves Tetraphase Pharma's antibiotic

Aug 27 The U.S. Food and Drug Administration on Monday approved Tetraphase Pharmaceuticals Inc's antibiotic for complicated intra-abdominal infections, providing a new option to combat the growing problem of treatment-resistant bacteria.

Aug 27 2018

Earnings vs. Estimates